Dopamine Agonists Market Size & Outlook, 2026-2034

Dopamine Agonists Market Overview

The global dopamine agonists market size is estimated at USD 1.35 billion in 2025 and is projected to reach USD 2.16 billion by 2034, growing at a CAGR of 5.41% during the forecast period. The remarkable growth of the market is due to the advancements in pharmacological research. In February 2024, as per the data published by the National Library of Medicine, several clinical trials demonstrated that novel dopamine agonist formulations, including long-acting and transdermal therapies, improved motor and non-motor symptoms in Parkinson’s patients, highlighting the impact of ongoing pharmacological innovations. Thus, continuous advancements in pharmacological research are enhancing the efficacy, safety, and patient adherence of dopamine agonist therapies.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 38.14% share in 2025.
• The Asia Pacific region is growing at the fastest pace, with a CAGR of 6.23%.
• Based on Indication, the Parkinson’s disease segment dominated the market in 2025 with a revenue share of 61.94%.
• Based on Drug Type, the ergot alkaloids segment is expected to register the fastest CAGR growth of 6.31%.
• Based on the Route of Administration, the oral segment dominated the market in 2025, with a revenue share of 55.62%.
• Based on Distribution Channel, the hospital pharmacies segment dominated the market in 2025, with a revenue share of 43.25%.
• The U.S. dominates the global market, valued at USD 458.00 million in 2024 and reaching USD 480.80 million in 2025.

Graph: U.S. Market Revenue Forecast (2022 – 2034)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 1.35 billion
• 2034 Projected Market Size: USD 2.16 billion
• CAGR (2025 to 2034): 5.41%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The global market encompasses a broad range of therapies designed to manage neurological and endocrine disorders by stimulating dopamine receptors, thereby improving patient outcomes and quality of life. By indication, the market includes Parkinson's disease, restless legs syndrome, hyperprolactinemia, and others, with Parkinson's disease leading the segment due to its high prevalence and the central role of dopamine agonists in its treatment regimen. By drug type, the market is classified into ergot alkaloids and non-ergot dopamine agonists, where non-ergot agonists hold a significant share owing to their better safety profile and growing clinical preference. By route of administration, dopamine agonists are available as oral, injectable, and other formulations, with oral medications dominating due to patient convenience and adherence. By distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and other pharmacies, where hospital pharmacies account for the major share as they serve as the primary point for prescribing and dispensing specialized neurological therapies.

Latest Market Trends

Shift from Ergot to Non-Ergot Dopamine Agonists

The global dopamine agonists market is experiencing a shift from ergot-derived dopamine agonists to non-ergot alternatives, driven by its improved safety profile and reduced risk of cardiovascular and fibrotic side effects. Thus, this transition from ergot to non-ergot dopamine agonists is reshaping the market, reflecting a growing emphasis on safer, more tolerable, and patient-centric treatment options for neurological disorders.

Emergence of Novel Drug Formulations

The global market is witnessing a trend towards the emergence of novel drug formulations, aimed at improving patient compliance, enhancing efficacy, and minimizing side effects. For example, in April 2025, Luye Pharma Group launched its rotigotine transdermal patch, Rotigotine Luye, in the UK. This product is indicated for the treatment of the signs and symptoms of early-stage and advanced idiopathic Parkinson's disease (PD) as well as moderate to severe idiopathic restless legs syndrome (RLS) in adults.

Thus, the development of novel drug formulations is driving market growth as it offers patient-friendly, efficient, and targeted therapeutic solutions for neurological disorders.

To get more insights about this report Download Free Sample Report

Dopamine Agonists Market Drivers

Increasing Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is a major driver shaping the growth of the global dopamine agonists market. For example, in March 2024, as per WHO, neurological conditions were the leading cause of illness and disability worldwide, which affected over 1 in 3 people globally.

Thus, the escalating prevalence of neurological disorders underscored a growing demand for efficient therapeutic solutions, positioning dopamine agonists as a critical component in managing these conditions. As the global burden of neurological diseases continues to rise, the market for dopamine agonists is expected to expand steadily, driven by the urgent need for improved patient outcomes and quality of life.

Market Restraint

The Decline in the Patent Publications of the Dopamine Agonists

The decline in the patent publications of the dopamine agonists hinders the market growth, as such a factor reduces the research momentum and scientific interest across the drug class.

The graph depicts patent publications for 2022–2025, highlighting a decline from 2023 to 2025 compared to 2022, indicating reduced innovation and intellectual property generation, which restrains the dopamine agonist market.

Graph: Patent publications year-wise

Source: Straits Research

Market Opportunity

Emerging Therapeutic Opportunities in Metabolic Management with Dopamine Agonists

A notable opportunity in the dopamine agonist market is the advancement of safer, targeted therapies aimed at managing metabolic disorders. According to the article published in the National Library of Medicine, researchers from the University of Pittsburgh developed bromocriptine methiodide (BrMeI), a molecule similar to FDA-approved bromocriptine, which does not cross the blood-brain barrier, highlighting its potential for safer metabolic management.

Such innovation underscored the expanding therapeutic potential of dopamine agonists beyond traditional neurological applications.

Regional Analysis

The North America region dominated the market with a revenue share of 38.14 % in 2025. The growth is attributed to factors such as the advanced healthcare infrastructure and widespread adoption of innovative dopamine agonist therapies.

The dopamine agonists market in the U.S. is widely driven by the focus on early Parkinson’s disease treatment. In 2024, AbbVie, Inc. announced positive Phase III results from its TEMPO-2 trial of Tavapadon, a first-in-class D1/D5 partial dopamine agonist. This innovation expanded treatment options, increased market size, and strengthened global market growth across neurology.

Asia Pacific Market Insights

The Asia Pacific region is the fastest-growing region with a CAGR of 6.23% during the forecast timeframe. The growth is attributed to factors such as increasing awareness about early neurological treatment, supportive government healthcare programs, and expanding access to advanced therapeutics across emerging economies, such as China and India.

The dopamine agonists market in China is fuelled by the country's evolving healthcare infrastructure and policy reforms. Recent government initiatives have focused on enhancing access to neurological treatments, including dopamine agonists, through improved reimbursement policies and expanded healthcare coverage. These efforts facilitated broader patient access to essential therapies, thereby contributing to the market's expansion and increased market size.

Pie Chart: Regional Market Share, 2025

Source: Straits Research

Europe Market Insights

The market in Europe is growing due to the economic and cost containment pressures that promote the adoption of affordable generic and biosimilar dopamine agonists across Europe. Patent expirations have intensified generic competition, lowering treatment costs for patients and healthcare payers while simultaneously encouraging branded manufacturers to innovate and differentiate their product portfolios.

The dopamine agonists market in the UK is propelling due to the Exenatide-PD3 trial. This is a UK government-funded Phase III study testing a once-weekly exenatide treatment over 96 weeks as a possible way to slow down Parkinson’s disease. The large scale of the trial and its public funding increase awareness, create more demand, and expand the market, supporting the growth of Dopamine Agonists by depicting new treatment options.

Middle East & Africa Market Insights

The market is growing due to the rapid growth of medical tourism in the Middle East and Africa, with countries like the UAE and Egypt emerging as regional hubs for specialized neurological care. These nations are attracting patients from neighbouring countries who seek advanced therapies, including dopamine agonists, thereby driving demand and supporting market expansion in the region.

The market in South Africa is growing due to the increasing integration of community-based healthcare programs and mobile clinics that improve access to neurological care in underserved regions. These initiatives support in the early diagnosis and management of movement disorders such as Parkinson’s disease and restless legs syndrome, expanding the patient base for dopamine agonists.

Latin America Market Insights

The increasing availability of government-subsidized chronic disease programs that cover neurological therapies drives the market growth. Public health initiatives in countries such as Brazil, Chile, and Mexico are expanding access to essential medications, including dopamine agonists, for patients with chronic diseases. This improved affordability and accessibility in both urban and semi-urban regions is encouraging wider adoption and fueling market growth.

Emergence of local pharmaceutical manufacturing and distribution initiatives for specialty medications enhances the market growth. Domestic production and improved supply chains are reducing dependency on imports, lowering costs, and ensuring more consistent availability of dopamine agonists across the country. This increased accessibility is encouraging wider adoption and driving market growth.

Indication Insights

The Parkinson’s disease segment dominated the market in 2025 with a revenue share of 61.94%. The growth is attributed to the increasing prevalence of Parkinson’s disease globally, rising geriatric population, and greater adoption of dopamine agonist therapies for efficient symptom management and improved patient quality of life.

Therestless legs syndrome segment is anticipated to register the fastest CAGR of 6.21%, owing to the rising prevalence of sleep-related movement disorders, increasing awareness and diagnosis rates, and the growing adoption of dopamine agonists as first-line therapy for managing moderate to severe restless legs syndrome symptoms.

Source: Straits Research

Drug Type Insights

The ergot alkaloids segment is anticipated to grow at a CAGR of 6.31% during 2026 - 2034. This growth is attributed to their established efficacy in treating hyperprolactinemia, increasing physician preference for long-acting formulations, and expanding availability in emerging markets where demand for affordable dopamine agonist therapies is rising.

The non-ergot dopamine agonists segment dominated the market in 2025, due to the favourable safety profile, lower risk of fibrotic complications, and better tolerability compared to ergot derivatives.

Route of Administration Insights

The oral segment dominated the market in 2025, with a revenue share of 55.62%. The growth is attributed to its ease of administration, higher patient compliance, and widespread availability compared to other dosage forms, making it the preferred choice for long-term management of Parkinson’s disease and related disorders.

The injectable segment is anticipated to register the fastest CAGR of 6.12% during the forecast period. This is due to the rising adoption of long-acting and continuous delivery formulations that offer improved patient compliance and steady plasma drug concentration.

Distribution Channel Insights

The hospital pharmacies dominated the market in 2025, with a revenue share of 43.25%. The growth is attributed to the increasing number of Parkinson’s and neurological patients seeking specialist care, the availability of a wide range of dopamine agonist therapies in hospitals, and the preference of physicians to dispense these medications through hospital pharmacies for better patient monitoring and adherence.

The drug stores & retail pharmacies are expected to register the fastest CAGR due to the rising availability of prescription dopamine agonists through retail channels, increasing patient preference for convenient medication access, and the expansion of organized pharmacy chains across emerging markets.

Competitive Landscape

The global dopamine agonists market is highly fragmented with the presence of numerous multinational and regional players such as Teva Pharmaceutical Industries Ltd, Supernus Pharmaceuticals, H. Lundbeck A/S, and Others.

AbbVie, Inc.: An emerging market player

AbbVie, Inc., is an emerging player in the global market, focused on advancing novel therapies for neurological disorders.

• In April 2024, AbbVie, Inc. developed tavapadon, a first-in-class D1/D5 partial dopamine agonist, into Phase III trials for early-stage Parkinson’s, depicting its focus on unmet patient needs.

List of key players in Dopamine Agonists Market

1. Teva Pharmaceutical Industries Ltd
2. Supernus Pharmaceuticals
3. Lundbeck A/S
4. AbbVie Inc.
5. Novartis AG
6. Amneal Pharmaceuticals LLC
7. Reddy’s Laboratories Ltd
8. Intas Pharmaceuticals Ltd.
9. GLENMARK PHARMACEUTICALS LTD.
10. Zydus Group
11. Hikma Pharmaceuticals PLC
12. TORRENT PHARMACEUTICALS LTD.
13. Apotex Inc.
14. Alto Neuroscience, Inc.
15. Mylan N.V.
16. Kyowa Kirin Co., Ltd.
17. Neurocrine Biosciences, Inc.,
18. Acorda Therapeutics, Inc.
19. Acadia Pharmaceuticals Inc.
20. Hoffmann-La Roche Ltd 
21. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• June 2025: Alto Neuroscience acquired ALTO-207, a dopamine agonist-based combination therapy (pramipexole and ondansetron) for the treatment of resistant depression.
• February 2025: Supernus Pharmaceuticals, Inc. announced the U.S. FDA approval of ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD).
• December 2024: AbbVie Inc. reported positive topline results from its Phase III TEMPO-2 trial, which evaluated tavapadon, a first-in-class D1/D5 partial dopamine agonist, as a flexible dose monotherapy for patients with early-stage Parkinson’s disease.